Stop VTE Prophylaxis at Discharge for Most COVID-19 Patients
January 1
New data will spark debate about the role of postdischarge venous thromboembolism (VTE) prophylaxis in COVID-19 patients.
We know that COVID-19 patients should receive VTE prophylaxis while hospitalized...which typically stops at discharge.
Now data suggest rivaroxaban (Xarelto) 10 mg daily for 35 days postdischarge in COVID-19 patients with HIGH clotting and LOW bleeding risk reduces VTE...without increasing bleeding.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote